Summary of Key Findings from Y-Track Phase 6 (2009–2012)
To promote and protect the health of Canadians through leadership, partnership, innovation and action in public health.
— Public Health Agency of Canada
Table of Contents
- Summary of key findings from Y-Track Phase 6 (2009–2012)
- Overview of Y-Track
- Key Findings
- Table 1. Demographic characteristics of Y-Track Phase 6 participants
- Table 2. Prevalence of HIV, hepatitis C, and other STBBIs among participants who provided a biological sample of sufficient quantity for testing
- Table 3. Alcohol and other drug use and related risk behaviours
- Table 4. Injection drug use and injecting related risk behaviours
- Table 5. Sexual risk behaviours
- Table 6. Self-reported testing and diagnosis for HIV and other sexually transmitted and blood-borne infections
- Table 7. Self-reported physical and mental health status and history of abuse
- Table 8. Health-related service knowledge, use and barriers
- Conclusions
- Acknowledgements
- References
- Appendix I:
- Footnotes
Download the alternative format
(PDF format, 1.3 MB, 28 pages)
Organization: Public Health Agency of Canada
Type: Report
Published: 2017-07-##
Summary of key findings from Y-Track Phase 6 (2009-2012)
This report provides an overview of findings from Y-Track Phase 6 (2009–2012). The data in this report are shown for the overall sample as well as by sex, allowing for comparisons between male and female participants. Where data in the table contain small cell countsFootnote i, interpret the results with caution.
Overview of Y-Track
What?
Y-Track (formerly E-SYS, Enhanced Surveillance of Canadian Street Youth) is an enhanced surveillance system that monitors rates of sexually transmitted and blood-borne infections (STBBIs) as well as the associated risk behaviours in the Canadian street youth population. Information is collected through cross-sectional surveys conducted periodically at sentinel sites across Canada. Consenting participants are asked to complete an interviewer-administered questionnaire covering demographics; drug use and injecting behaviours; sexual behaviours; history of testing and diagnosis of the human immunodeficiency virus (HIV) and other STBBIs; self-reported physical and mental status; history of abuse; and health service knowledge, use, and barriers. Survey participants are asked to provide consent for one or more of the following biological tests: HIV, hepatitis C (HCV), herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), hepatitis B (HBV), chlamydia, syphilis, gonorrhea, and human T-lymphotropic virus (HTLV). Y-Track is the only non-school based, national level behavioural and biological surveillance system for this population in Canada. Please refer to Appendix 1 for details of the testing methods used and the interpretation of test results.
Who?
The target population is youth between 15 and 24 years old who have not lived at home for at least 3 consecutive days in the 6 months preceding the survey; who are able to understand spoken English or French; and who provide informed consent. Participation is voluntary and completely anonymous.
When and Where?
Survey participants are recruited from sentinel sites across Canada. The Y-Track Phase 1 was conducted in 1998 in 3 sites, followed by 5 more cycles of data collection: Phase 2 in 1999 in 7 sites, Phase 3 in 2001 in 6 sites, Phase 4 in 2003 in 7 sites, and Phase 5 in 2005–2006 in 6 sites. The most recent cycle of data collection, Phase 6, was conducted in 2009–2012 in 8 sentinel sites: Vancouver (British Columbia), Edmonton (Alberta), Saskatoon (Saskatchewan), Winnipeg (Manitoba), Toronto (Ontario), Ottawa (Ontario), Montréal (Quebec), Halifax (Nova Scotia) (Figure 1).
Why?
Street-involved youth in Canada are vulnerable to HIV infection and other STBBIs as a result of many factors, including sexual behaviours that increase their risk of exposure to STBBIs, substance use (including injection drug use), and misinformation about or lack of information on HIV transmission. The ongoing monitoring of risk behaviours among street-involved youth who engage in high risk behaviours can serve as an early warning system for the spread of blood-borne infections in Canada. Survey results can also help inform and evaluate existing public health responses to HIV and other STBBIs among street-involved youth in Canada.
Figure 1. Y-Track Phase 6 (2009–2012) sentinel sites
Figure 1 - Text Description
The map of Canada presents the Y-Track Phase 6 sites. From west to east, the participating sites were: Vancouver (BC), Edmonton (AB), Saskatoon (SK), Winnipeg (MB), Toronto (ON), Ottawa (ON), Montreal (QC), and Halifax (NS).Key Findings
A total of 1425 eligible participants were recruited across all sentinel sites during Y-Track Phase 6. Eligible participants who were transgender (n=14) or whose biological sex was not recorded (n=4) were excluded from the analyses as small numbers prevent meaningful interpretation. Data for the remaining 1407 participants were presented in this report.
Demographic characteristics | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
Age in years (n=1407) | ||||
15–19 | 45.9 (646) | 40.2 (348) | 55.0 (298) | <0.001 |
20–24 | 54.1 (761) | 59.8 (517) | 45.0 (244) | |
Sexual orientation (n=1403) | ||||
Heterosexual or straight | 75.1 (1053) | 86.1 (742) | 57.5 (311) | <0.001 |
Homosexual | 3.0 (42) | 2.7 (23) | 3.5 (19) | |
Bisexual | 18.1 (254) | 9.0 (78) | 32.5 (176) | |
Other sexual orientationTable 1 Footnote a | 3.8 (54) | 2.2 (19) | 6.5 (35) | |
Country of birth (n=1397) | ||||
Canada | 92.8 (1296) | 92.3 (791) | 93.5 (505) | 0.446 |
Outside Canada, HIV-endemic countryTable 1 Footnote b | 1.9 (26) | 2.2 (19) | 1.3 (7) | |
Outside Canada, non-endemic countryTable 1 Footnote c | 5.4 (75) | 5.5 (47) | 5.2 (28) | |
Self-reported ethnicity (n=1398) | ||||
Aboriginal | 34.2 (478) | 32.8 (282) | 36.4 (196) | 0.141 |
Black | 5.1 (71) | 5.7 (49) | 4.1 (22) | |
Caucasian | 46.2 (646) | 47.8 (411) | 43.6 (235) | |
Other ethnicityTable 1 Footnote d | 14.5 (203) | 13.6 (117) | 16.0 (86) | |
Level of education (n=1397) | ||||
Completed some high school or less | 75.0 (1048) | 73.8 (633) | 77.0 (415) | 0.360 |
Completed high school | 20.5 (286) | 21.7 (186) | 18.6 (100) | |
Completed more than high school | 4.5 (63) | 4.5 (39) | 4.5 (24) | |
Kicked out of school permanentlyTable 1 Footnote e (n=1400) | ||||
42.2 (591) | 49.7 (428) | 30.2 (163) | <0.001 | |
Main source of income (n=1372) | ||||
Government and/or insurance | 40.2 (552) | 35.2 (296) | 48.1 (256) | <0.001 |
Work, on a regular basis | 19.8 (272) | 24.8 (208) | 12.0 (64) | |
Family or friends | 12.9 (177) | 9.8 (82) | 17.9 (95) | |
Sex work | 3.1 (43) | 1.9 (16) | 5.1 (27) | |
Selling drugs | 9.1 (125) | 11.7 (98) | 5.1 (27) | |
Street-based activitiesTable 1 Footnote f | 8.2 (112) | 8.6 (72) | 7.5 (40) | |
Other source of incomeTable 1 Footnote g | 6.6 (91) | 8.1 (68) | 4.3 (23) | |
Location where the participant slept most often in the 3 months prior to the interview (n=1404) | ||||
Own room or apartment or house | 19.2 (269) | 18.1 (156) | 20.9 (113) | <0.001 |
Caregiver's place or group homeTable 1 Footnote h | 18.2 (255) | 16.5 (142) | 20.9 (113) | |
Friend or partner's place | 18.9 (266) | 18.9 (163) | 19.0 (103) | |
Shelter or hostel | 22.0 (309) | 26.1 (225) | 15.5 (84) | |
Public placesTable 1 Footnote i | 10.8 (151) | 10.2 (88) | 11.6 (63) | |
Different place almost every night | 6.2 (87) | 5.0 (43) | 8.1 (44) | |
Other sleep locationTable 1 Footnote j | 4.8 (67) | 5.3 (46) | 3.9 (21) | |
Lived in foster care in the 12 months prior to the interview (n=1406) | ||||
7.0 (99) | 6.0 (52) | 8.7 (47) | 0.058 | |
History of incarcerationTable 1 Footnote k (n=1397) | ||||
68.5 (957) | 78.2 (673) | 53.0 (284) | <0.001 | |
Abbreviations: HIV, human immunodeficiency virus. Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on the chi square (χ2) statistic.
|
The demographic characteristics of Y-Track Phase 6 participants were similar to those of previous Y-Track phases. More of the participants were male (61.5%), although the proportion varied by age group: at 20 to 24 years of age, 59.8% of the participants were male and 45.0% were female; conversely, at 15 to 19 years of age, 55.0% were female and 40.2% were male.
Three-quarters of Y-Track Phase 6 participants self-reported their sexual orientation as heterosexual or straight (75.1%). A higher proportion of female participants self-identified as homosexual (3.5% versus 2.7% for male participants), bisexual (32.5% versus 9.0%), or another sexual orientation (i.e., Queer, Questioning, etc.; 6.5% versus 2.2%).
The majority of participants reported Canada as their country of birth (92.8%). Only 5.4% reported being born in a non-endemic country outside Canada and 1.9% from an HIV-endemic country. No statistically significant differences were found between male and female participants.
The largest proportion of participants self-identified as Caucasian (46.2%), but just over one-third (34.2%) self-identified as Aboriginal (i.e., First Nations, Métis, or Inuit), a rate almost 8 times higher than the proportion of Aboriginal people in the general Canadian population in 2011 (4.3%)Footnote 1. Only 5.1% self-identified as Black and 14.5% as other ethnicities. Male and female participants did not differ significantly in terms of distribution of self-reported ethnicities.
Three-quarters of participants reported not completing high school (75.0%) and over one-third (42.2%) reported being expelled from school. While male and female participants did not differ significantly in reported level of education attained, a higher proportion of male participants reported being permanently expelled (49.7% versus 30.2% for female participants).
Over one-third (40.2%) of participants reported that their main income source was from government and/or insurance sources. A higher proportion of female participants reported government and/or insurance sources as their main income source (48.1% versus 35.2% for male participants) or family or friends (17.9% versus 9.8%) or sex work (5.1% versus 1.9%), while a higher proportion of male participants reported regular work (24.8% versus 12.0% for female participants) as their main income source.
Nearly one-quarter (22.0%) of participants, and particularly male participants (26.1% versus 15.5% for female participants), reported sleeping most often in a shelter or hostel in the 3 months prior to the interview. The other most common locations included their own room or apartment or house (19.2%), a friend or partner’s place (18.9%), and a caregiver’s place or a group home (18.2%). A small proportion (7.0%) (with similar proportions of male and female participants) reported living in foster care in the 12 months prior to the interview. Just over two-thirds (68.5%) reported a history of incarceration (i.e., detention facility, youth detention centre, prison or jail), with a higher proportion of male participants reporting a history of incarceration (78.2% versus 53.0% for female participants).
Infection or exposure indicator | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
HIV infection (n=1076) | ||||
HIV seropositive | 0.9 (10) | 0.9 (6) | 1.0 (4) | 1.0Table 2 Footnote a |
HIV seronegative | 99.1 (1066) | 99.1 (668) | 99.0 (398) | |
Lifetime exposure to hepatitis C (n=1076) | ||||
Hepatitis C seropositive | 5.6 (60) | 4.7 (32) | 7.0 (28) | 0.174 |
Hepatitis C seronegative | 94.1 (1013) | 95.1 (641) | 92.5 (372) | |
Indeterminate | 0.3 (3) | 0.1 (1) | 0.5 (2) | |
HSV-1 exposure (n=1076) | ||||
HSV-1 seropositive | 53.3 (574) | 49.9 (336) | 59.2 (238) | 0.008 |
HSV-1 seronegative | 46.5 (500) | 49.9 (336) | 40.8 (164) | |
Indeterminate | 0.2 (2) | 0.3 (2) | 0.0 (0) | |
HSV-2 exposure (n=1076) | ||||
HSV-2 seropositive | 13.4 (144) | 7.6 (51) | 23.1 (93) | <0.001 |
HSV-2 seronegative | 86.3 (929) | 92.1 (621) | 76.6 (308) | |
Indeterminate | 0.3 (3) | 0.3 (2) | 0.2 (1) | |
Hepatitis B infection status (n=1114) | ||||
Susceptible | 30.9 (344) | 33.7 (237) | 26.1 (107) | 0.084 |
Immunity due to natural infection with hepatitis B | 0.6 (7) | 0.7 (5) | 0.5 (2) | |
Vaccine-mediated immunity to hepatitis B | 62.3 (694) | 59.4 (418) | 67.3 (276) | |
Currently infected (acute or chronic) | 0.1 (1) | 0.1 (1) | 0.0 (0) | |
Uninterpretable lab result | 6.1 (68) | 6.1 (43) | 6.1 (25) | |
Chlamydia infection at time of test (n=1237) | ||||
Positive | 8.7 (107) | 7.5 (57) | 10.5 (50) | <0.001 |
Negative | 90.2 (1116) | 92.4 (704) | 86.7 (412) | |
Indeterminate | 1.1 (14) | 0.1 (1) | 2.7 (13) | |
Lifetime exposure to syphilis (n=1105) | ||||
Positive | 0.8 (9) | 0.7 (5) | 1.0 (4) | 0.800Table 2 Footnote a |
Negative | 99.2 (1096) | 99.3 (695) | 99.0 (401) | |
Gonorrhea infection at time of test (n=1235) | ||||
Positive | 1.0 (12) | 0.7 (5) | 1.5 (7) | <0.001 |
Negative | 98.0 (1210) | 99.2 (756) | 96.0 (454) | |
Indeterminate | 1.1 (13) | 0.1 (1) | 2.5 (12) | |
Abbreviations: HIV, human immunodeficiency virus; HSV-1, herpes simplex virus-1; HSV-2, herpes simplex virus-2; STBBIs, sexually transmitted and blood-borne infections. Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on the chi square (χ2) statistic unless specified otherwise. See Appendix I for details on testing methods and interpretation of test results.
|
HIV
Of the 1076 participants who provided a blood sample sufficiently large to be tested for HIV, 10 (0.9%) were found to be HIV positive. HIV seroprevalence was similar in male (0.9%) and in female (1.0%) participants. These proportions are higher than the estimated HIV prevalence rate in Canada in 2011 (208 per 100 000 population, or 0.208%).Footnote 2
Hepatitis C
A small proportion of participants (5.6%) were seropositive for hepatitis C. This is higher than the 2010Footnote ii national reported rateFootnote iii of hepatitis C infection among youth aged 15 to 24 (17.9 per 100 000 population, or 0.018%).Footnote 3
Although a smaller proportion of male participants were seropositive for hepatitis C (4.7% versus 7.0% for female participants), this difference was not statistically significant. This is similar to the 2010 national reported ratesFootnote iii of hepatitis C for youth aged 15 to 24: rates for males were slightly lower than for females (16.4 per 100 000 population or 0.016% versus 19.4 per 100 000 population or 0.019%).Footnote 3
Herpes simplex virus-1 and herpes simplex virus-2
Over half (53.3%) of all participants tested positive for herpes simplex virus-1 (HSV-1) infection, with a higher proportion of female participants HSV-1 seropositive (59.2% versus 49.9% for male participants). Overall, 13.4% of the participants were positive for herpes simplex virus-2 (HSV-2), with a higher proportion of female participants testing positive (23.1% versus 7.6% for male participants). Population-based, national-level data on genital HSV infections in Canada are not availableFootnote 4; however, the proportions of Y-Track Phase 6 participants seropositive for HSV-1 and HSV-2 are similar to the results of previous Y-Track phases.Footnote 5
Hepatitis B
Just under two-thirds (62.3%) of participants had vaccine-mediated immunity to hepatitis B, and just under one-third (30.9%) were susceptible to hepatitis B. Only 0.1% participants had a current hepatitis B infection (acute or chronic) and only 0.6% had a past infection. These proportions are higher than the 2010 national reported ratesFootnote iii for youth aged 15 to 24 (5.7 per 100 000 population or 0.006%).Footnote 3 While the differences between male and female Y-Track Phase 6 participants were not significant, the 2010 national reported ratesFootnote iii of infection were higher for female than male youth aged 15 to 24 (6.6 per 100 000 population or 0.007% versus 4.8 per 100 000 population or 0.005%).Footnote 3
Chlamydia
Overall, 8.7% of participants tested positive for chlamydia, higher than the 2010 national ratesFootnote iii of infection in youth aged 15 to 24 (1300.3 per 100 000 population or 1.300%). A higher proportion of female Y-Track Phase 6 participants were found to have a chlamydia infection at the time of testing (10.5% versus 7.5% for male participants). These findings are striking as these rates are nearly 6 times higher than the 2010 national reported ratesFootnote iii of chlamydia infection among female youth (1912.4 per 100 000 population or 1.912%) and nearly 11 times higher than the same rate among male youth (710.6 per 100 000 population or 0.711%).Footnote 3
Syphilis
Syphilis seropositivity at the time of testing (i.e., a current syphilis infection, a previously treated syphilis infection, or a previously untreated syphilis infection) was 0.8% among participants who provided a biological sample large enough to test (n=1106). This proportion is 133 times higher than the 2010 reported national rateFootnote iii for syphilis infection in youth aged 15 to 24 (6.4 per 100 000 population or 0.006%).Footnote 3 Infection with syphilis was slightly higher among female Y-Track Phase 6 participants (1.0% versus 0.7% for male participants); however, this difference was not statistically significant. The 2010 national reported syphilis infection ratesFootnote iii were 3 times higher among male youth aged 15 to 24 (9.7 per 100 000 population or 0.01%) than among female youth the same age (3.0 per 100 000 population or 0.003%).Footnote 3
Gonorrhea
Of the 1235 participants who provided a biological sample large enough to test, 1.0% tested positive for gonorrhea at the time of testing. This proportion is 8 times higher than the 2010 reported national ratesFootnote iii for youth aged 15 to 24 (121.6 per 100 000 population, or 0.122%).Footnote 3 A higher proportion of female Y-Track Phase 6 participants tested positive for gonorrhea (1.5% versus 0.7% for male participants). These proportions are 10 times higher than the 2010 national reported rateFootnote iii for gonorrhea infection among female youth aged 15 to 24 (142.8 per 100 000 population or 0.143%) and 7 times higher among male youth the same age (101.2 per 100 000 population or 0.101% ).Footnote 3
Human T-lymphotropic virus
None of the participants tested (n=1074) were positive for human T-lymphotropic virus (data not shown in Table 2).
Alcohol or drug use behaviour | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
Frequency of alcohol consumption in the 3 months prior to the interview (of participants who reported drinking in the 12 months prior to the interview, n=1289) | ||||
Never in past 3 months | 7.1 (91) | 5.7 (46) | 9.2 (45) | 0.092 |
Up to 3 times a month | 41.4 (533) | 41.9 (336) | 40.4 (197) | |
Up to 6 times a week | 37.9 (489) | 37.8 (303) | 38.1 (186) | |
Daily | 13.7 (176) | 14.5 (116) | 12.3 (60) | |
Frequency of binge drinkingTable 3 Footnote a in the 3 months prior to the interview (of participants who reported binge drinking in the 12 months prior to the interview, n=854) | ||||
Never in past 3 months | 11.6 (99) | 10.8 (57) | 12.9 (42) | 0.579 |
Up to 3 times a month | 45.6 (389) | 45.6 (241) | 45.5 (148) | |
Up to 6 times a week | 34.1 (291) | 34.0 (180) | 34.2 (111) | |
Daily | 8.8 (75) | 9.6 (51) | 7.4 (24) | |
Frequency of cigarette smoking at the time of the interview (n=1399) | ||||
Does not currently smoke | 14.1 (197) | 12.5 (108) | 16.6 (89) | 0.039 |
Occasionally smokes | 10.7 (150) | 11.8 (102) | 8.9 (48) | |
Smokes every day | 75.2 (1052) | 75.6 (652) | 74.5 (400) | |
Proportion who used any drugs by non-injection route in the 12 months prior to the interview (of participants who reported ever using non-injection drugs, n=1348) | ||||
96.7 (1304) | 98.0 (813) | 95.0 (491) | 0.002 | |
Drugs used most often by non-injection route in the 12 months prior to the interview (of participants who reported using non-injection drugs in the 12 months prior to the interview, n=1284) | ||||
Marijuana | 72.7 (933) | 78.2 (626) | 63.6 (307) | <0.001 |
Cocaine | 10.7 (138) | 7.6 (61) | 15.9 (77) | |
MDMA (Ecstasy) | 4.8 (61) | 3.6 (29) | 6.6 (32) | |
Amphetamines | 2.4 (31) | 2.5 (20) | 2.3 (11) | |
Hallucinogens | 2.3 (29) | 2.6 (21) | 1.7 (8) | |
OtherTable 3 Footnote b | 7.2 (92) | 5.5 (44) | 9.9 (48) | |
Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on chi square (χ2) statistic. See Appendix I for details on testing methods and interpretation of test results.
|
Street-involved youth have higher rates of substance use compared to the general youth population, which is an ongoing public health concern.Footnote 6 Use of alcohol and/or drugs has been shown to affect sexual behaviour by increasing risk taking (e.g., inconsistent condom use, multiple sex partners) and overall vulnerability to STBBI.Footnote 7
Alcohol
Of the 1289 participants who reported consuming alcohol in the 12 months prior to the interview, 41.4% reported drinking up to 3 times per week, 37.9% reported drinking up to 6 times a week, and 13.7% reported drinking every day in the 3 months prior to the interview. A small proportion reported no alcohol consumption during this period (7.1%). No statistically significant differences were noted between male and female participants. In comparison, the 2010 Canadian Alcohol and Drug Use Monitoring Survey (CADUMS, n=13 615) found that 71.5% of the Canadian youth aged 15 to 24 who participated in the survey reported alcohol use in the previous year.Footnote 8
Of the 854 participants who reported binge drinking in the 12 months prior to the interview, 45.6% reported binge drinking up to 3 times per week, 34.1% reported binge drinking up to 6 times a week, and 8.8% reported binge drinking every day in the 3 months prior to the interview. A small proportion reported no binge drinking during this period (11.6%). Male and female participants did not differ significantly in terms of reported frequency of binge drinking. The proportion of Y-Track participants who indicated binge drinking in the year prior to the interview (60.6%) was over 6 times the proportion of same age youth who reported heavy drinkingFootnote iv in the 2010 CADUMS.Footnote 8
Cigarettes
Over three-quarters of participants (85.9%) reported smoking cigarettes at the time of the interview. Of these, 10.7% reported smoking occasionally and 75.2% reported smoking every day, with male and female participants not differing significantly in terms of smoking frequency. In comparison, the general youth population aged 15 to 24 in Canada has a smoking prevalence of 17% as reported in the 2010 Canadian Tobacco Use Monitoring Survey (CTUMS).Footnote 9
Non-injection drugs
The majority of participants (96.7%) indicated they had used drugs by non-injection routes in the 12 months prior to the interview, with marijuana (72.7%) and cocaine (10.7%) being the most commonly used drugs. Smaller proportions of other drugs used included MDMA (Ecstasy) (4.8%), amphetamines (2.4%), hallucinogens (2.3%), and other drug classes (7.2%).
The type of drug used predominantly differed between male and female participants. A larger proportion of male participants reported marijuana as the most commonly used drug (78.2% versus 63.6% for female participants), while a larger proportion of female participants reported using cocaine (15.9% versus 7.6% for male participants).
Injection drug use behaviour | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
Proportion who had ever injected drugs (n=1403) | ||||
22.0 (308) | 21.9 (189) | 22.1 (119) | 0.929 | |
Proportion who injected drugs in the 12 months prior to the interview (of participants who injected more than once in their lifetime, n=240)Table 4 Footnote a | ||||
78.8 (189) | 79.3 (119) | 77.8 (70) | 0.776 | |
Drugs most often injected in the 12 months prior to the interview (of participants who injected more than once in the 12 months prior to the interview, n=181)Table 4 Footnote a | ||||
Heroin | 24.9 (45) | 24.1 (27) | 26.1 (18) | 0.371 |
Cocaine | 18.2 (33) | 16.1 (18) | 21.7 (15) | |
Morphine | 18.2 (33) | 15.2 (17) | 23.2 (16) | |
Methamphetamines | 13.8 (25) | 17.0 (19) | 8.7 (6) | |
Dilaudid | 12.7 (23) | 14.3 (16) | 10.1 (7) | |
OtherTable 4 Footnote b | 12.2 (22) | 13.4 (15) | 10.1 (7) | |
Proportion who injected with used needles and/or syringes (of participants who had injected drugs in the 12 months prior to the interview) (n=247) | ||||
32.8 (81) | 25.8 (39) | 43.8 (42) | 0.003 | |
Proportion who had ever injected with other used injection equipmentTable 4 Footnote c (of participants who had injected drugs in the 12 months prior to the interview, n=240) | ||||
42.1 (101) | 38.4 (56) | 47.9 (45) | 0.145 | |
Proportion who used sterile needles and/or syringes in the 3 months prior to the interview (of participants who had injected drugs in the 3 months prior to the interview, n=155) | ||||
Never | 8.4 (13) | 7.2 (7) | 10.3 (6) | 0.646 |
Less than 50% of the time | 9.0 (14) | 7.2 (7) | 12.1 (7) | |
More than 50% of the time | 20.6 (32) | 21.6 (21) | 19.0 (11) | |
All of the time | 61.9 (96) | 63.9 (62) | 58.6 (34) | |
Proportion who had ever been tattooed (n=1407) | ||||
By a professional | 21.5 (303) | 18.4 (159) | 26.6 (144) | <0.001 |
By a non-professional | 26.4 (371) | 24.9 (215) | 28.8 (156) | |
Never tattooed | 52.1 (733) | 56.8 (491) | 44.6 (242) | |
Proportion who had ever been pierced (n=1407) | ||||
By a professional | 51.5 (725) | 37.3 (323) | 74.2 (402) | <0.001 |
By a non-professional | 25.6 (360) | 27.9 (241) | 22.0 (119) | |
Never pierced | 22.9 (322) | 34.8 (301) | 3.9 (21) | |
Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on chi square (χ2) statistic.
|
Injection drug use was reported by just under one-quarter of all participants (22.0%). In comparison, less than 2% of the Canadian general youth population 15 years of age or older injected drugs.Footnote 10 Footnote 11 Of the participants who reported injecting more than once in their lifetime, over three-quarters (78.8%) reported they had injected drugs in the 12 months prior to the interview. The participants who reported injecting drugs more than once in the 12 months prior to the interview most commonly injected heroin (24.9%), cocaine (18.2%), and morphine (18.2%). There were no statistically significant differences between female and male participants in terms of type of drugs injected.
Of the participants who had injected drugs at least once in the 12 months prior to the interview, 32.8% reported injecting with used needles and/or syringes and 42.1% reported injecting with other used injection equipment (i.e., water, filters, swabs, and cookers). A larger proportion of female participants reported injecting drugs with used needles and/or syringes (43.8% versus 25.8% for male participants), while female and male participants did not differ significantly in reporting injecting with other used injection equipment.
Of the 155 participants who reported injecting drugs in the 3 months prior to the interview, 61.9% reported always using a sterile needle and 20.6% reported using a sterile needle more than 50% of the time. Small proportions reported using a sterile needle less than 50% of the time (9.0%) or never using a sterile needle (8.4%). Female and male participants did not differ significantly in reporting sterile needle and/or syringe use.
Getting tattooed by a non-professional was reported by 26.4% of all participants compared to 21.5% getting tattooed by a professional. A higher proportion of female participants reported getting tattooed by a non-professional (28.8% versus 24.9% for male participants). Getting pierced by a non-professional was reported by 25.6% of all participants compared to 51.5% getting pierced by a professional. A higher proportion of male participants reported getting pierced by a non-professional (27.9% versus 22.0% for female participants).
Sexual behaviours | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
Perceived risk of acquiring an STBBI (n=1362) | ||||
No risk | 20.0 (273) | 18.4 (155) | 22.6 (118) | 0.191 |
Low risk | 45.2 (615) | 47.1 (396) | 42.0 (219) | |
Medium risk | 26.9 (367) | 26.6 (224) | 27.4 (143) | |
High risk | 7.9 (107) | 7.8 (66) | 7.9 (41) | |
Lifetime number of sex partners (of participants who had ever had sex, n=1322) | ||||
One | 3.4 (45) | 3.2 (26) | 3.7 (19) | 0.655 |
Two or more | 96.6 (1277) | 96.8 (780) | 96.3 (497) | |
Number of sex partners in the 3 months prior to the interview (of participants who had ever had sex, n=1134) | ||||
One | 42.3 (480) | 38.7 (259) | 47.6 (221) | 0.003 |
Two or more | 57.7 (654) | 61.3 (411) | 52.4 (243) | |
Age at first vaginal sex (of participants who had ever had vaginal sex, n=1277) | ||||
12 years or under | 19.3 (247) | 21.3 (165) | 16.4 (82) | 0.029 |
13 to 15 years | 49.3 (629) | 47.0 (365) | 52.7 (264) | |
16 to 18 years | 28.7 (367) | 29.6 (230) | 27.3 (137) | |
19 years or older | 2.7 (34) | 2.1 (16) | 3.6 (18) | |
Proportion who reported condomTable 5 Footnote a or dental dam use at last oral sex (of participants who reported ever having oral sex, n=1210) | ||||
21.0 (254) | 19.9 (148) | 22.7 (106) | 0.248 | |
Proportion who reported condomTable 5 Footnote a use at last vaginal sex (of participants who reported ever having vaginal sex, n=1309) | ||||
51.0 (668) | 53.4 (427) | 47.3 (241) | 0.029 | |
Proportion who reported condomTable 5 Footnote a use at last anal sex (of participants who reported ever having anal sex, n=606) | ||||
56.8 (344) | 59.2 (229) | 52.5 (115) | 0.112 | |
Frequency of condom use during any type of sex in the 3 months prior to the interview (of participants who reported ever having sex, n=1175) | ||||
Never used a condom | 29.4 (345) | 26.8 (187) | 33.1 (158) | 0.002 |
Used a condom less than 50% of the time | 24.1 (283) | 23.8 (166) | 24.5 (117) | |
Used a condom 50%–99% of the time | 25.6 (301) | 24.9 (174) | 26.6 (127) | |
Used a condom 100% of the time | 20.9 (246) | 24.5 (171) | 15.7 (75) | |
Proportion who were drunk and/or high during sex in the 3 months prior to the interview (n=1179) | ||||
83.7 (987) | 85.8 (603) | 80.7 (384) | 0.020 | |
Abbreviations: STBBI, sexually transmitted and blood-borne infection. Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on chi square (χ2) statistic.
|
Self-perceived risk of STBBI
Conditions of poverty, violence, and abuse often persist on the streets, leading street-involved youth to engage in negative coping mechanisms and risk behaviours (e.g., substance use, inconsistent condom use) that make them more vulnerable to an STBBI.Footnote 12 Of all survey participants, 20.0% perceived themselves as having no risk of acquiring an STBBI, 45.2% perceived themselves at low risk, 26.9% perceived themselves at medium risk, and only 7.9% perceived themselves to be at high risk of acquiring an STBBI. No statistically significant differences were found between female and male participants.
Number of sexual partners
Of the participants who reported ever having sex, the majority (96.6%) reported having two or more sexual partners in their lifetime; male and female participants did not differ significantly in reporting numbers of sexual partners.
Of the participants who reported having sex in the three months prior to the interview, 57.7% reported two or more sexual partners. A higher proportion of male participants reporting two or more sexual partners (61.3% versus 52.4% for female participants).
Age at first vaginal sex
Half of the participants (49.3%) indicated they were between 13 and 15 years old the first time they engaged in vaginal sex; 19.3% were 12 years or younger, 28.7% were 16 to 18 years of age, and 2.7% were 19 years or older. Of the 19.3% who reported being 12 years of age or younger the first time they engaged in vaginal sex, 21.3% were male and 16.4% were female. A significant difference was found between male and female participants across age groupings.
Condom use during vaginal sex
Of the participants who reported ever having vaginal sex, 51.0% reported using a condom the last time they had vaginal sex, with a significant difference in use between male and female participants (53.4% versus 47.3%).
Condom use during oral sex
Of the participants who reported ever having oral sex, 21.0% reported using a condom or dental dam the last time they had oral sex, with no significant difference in use between male and female participants (19.9% versus 22.7%).
Condom use during anal sex
Of the participants who reported ever having anal sex, 56.8% reported using a condom the last time they had anal sex, with no significant difference in use between male and female participants (59.2% versus 52.5%).
Condom use during any type of sex
Of the participants who reported ever having sex, 29.4% reported never using a condom, 24.1% used a condom less than 50% of the time, 25.6% used a condom 50% to 99% of the time, and 20.9% used a condom 100% of the time.
Sex under the influence of alcohol or drugs
Of the participants who had sex in the 3 months prior to the interview, 83.7% reported being drunk and/or high during sex. A significantly higher proportion of male participants reported being drunk and/or high during sex (85.8% versus 80.7% for female participants).
Self-reported testing and diagnosis | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
HIV | ||||
Proportion who have been tested for HIV (n=1390) | 66.0 (917) | 62.6 (534) | 71.3 (383) | 0.001 |
Proportion who reported previous diagnosis with an HIV infectionTable 6 Footnote a (n=1398) | 1.0 (14) | 0.6 (5) Table 6 Footnote b | 1.7 (9)Table 6 Footnote b | 0.046 |
Hepatitis C | ||||
Proportion who have been tested for hepatitis C (n=1390) | 55.3 (769) | 52.9 (451) | 59.2 (318) | 0.021 |
Proportion who reported previous diagnosis with hepatitis CTable 6 Footnote c (n=1397) | 4.5 (63) | 3.3 (28) | 6.5 (35) | 0.004 |
Hepatitis B | ||||
Proportion who have been tested for hepatitis B (n=1390) | 43.6 (606) | 41.0 (350) | 47.7 (256) | 0.015 |
Proportion who reported previous diagnosis with hepatitis BTable 6 Footnote d (n=1399) | 0.8 (11) | 0.5 (4) | 1.3 (7) | 0.118Table 6 Footnote e |
Self-reported testing for Sexually Transmitted Infections (STIs) | ||||
Proportion who have been tested for any STI (n=1390) | 65.8 (914) | 59.2 (505) | 76.2 (409) | <.001 |
Among those who have been tested for an STI (n=914) | ||||
Proportion who have been tested for chlamydia (n=904) | 95.9 (867) | 94.8 (473) | 97.3 (394) | 0.060 |
Proportion who have been tested for gonorrhea (n=904) | 96.1 (869) | 94.8 (473) | 97.8 (396) | 0.021 |
Proportion who have been tested for syphilis (n=903) | 74.2 (670) | 75.6 (377) | 72.5 (293) | 0.301 |
Proportion who reported previous diagnosis with chlamydiaTable 6 Footnote f (n= 912) | 28.2 (257) | 21.2 (107) | 36.9 (150) | <0.001 |
Proportion who reported previous diagnosis with gonorrheaTable 6 Footnote g (n= 909) | 11.1 (101) | 9.3 (47) | 13.3 (54) | 0.059 |
Proportion who reported previous diagnosis with syphilisTable 6 Footnote h (n= 912) | 1.6 (15) | 1.6 (8) | 1.7 (7) | 0.873 |
Abbreviations: HIV, human immunodeficiency virus; STIs, sexually transmitted infections. Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on chi square (χ2) statistic unless otherwise indicated.
|
Self-reported HIV testing and diagnosis
Two-thirds of all participants had been tested for HIV (66.0%) with a significantly higher proportion of female participants reporting ever being tested (71.3% versus 62.6% for male participants). Overall, 1.0% of participants reported having been previously diagnosed with HIV, and a slightly but significantly higher proportion of female participants reported this (1.7% versus 0.6% for male participants). Not all the participants who reported a previous diagnosis with HIV consented to testing for this survey. As a result, Table 2 shows the proportion of HIV-seropositive participants (0.9%) to be smaller than the proportion reporting a previous diagnosis.
Self-reported hepatitis C testing and diagnosis
Over half of all participants had been tested for hepatitis C (55.3%) with a significantly higher proportion of female participants reporting ever being tested (59.2% versus 52.9% for male participants). Overall, 4.5% of participants—and a significantly higher proportion of female participants (6.5% versus 3.3% for male participants)—reported being previously diagnosed with hepatitis C.
Self-reported hepatitis B testing and diagnosis
Overall, 43.6% of all participants had been tested for hepatitis B with a significantly higher proportion of female participants reporting ever being tested (47.7% versus 41.0% for male participants). Overall, 0.8% of all participants reported a previous diagnosis with hepatitis B; no statistically significant differences were found between male and female participants.
Self-reported sexually transmitted infection testing and diagnosis
Overall, 65.8% of participants—and a significantly larger proportion of female participants—reported ever being tested for sexually transmitted infections (STIs) (76.2% versus 59.2% male participants). Of these, the majority had been tested for chlamydia (95.9%) and gonorrhea (96.1%); nearly three-quarters had ever been tested for syphilis (74.2%). There were no statistically significant differences between female and male participants in terms of specific STI testing except that a significantly higher proportion of female participants reported having been tested for gonorrhea (97.8% versus 94.8% for male participants).
Of the participants who had been tested for an STI, 28.2% reported they had been previously diagnosed with chlamydia, 11.1% with gonorrhea, and 1.6% with syphilis. Apart from a significantly higher proportion of female participants reporting a previous diagnosis of chlamydia (36.9% versus 21.2% for male participants), no statistically significant differences were noted between male and female participants regarding previous STI diagnoses.
Self-reported health status, and history of abuse | All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value |
---|---|---|---|---|
Physical health status | ||||
Self-reported physical health status at time of interview (n=1395) | ||||
Poor | 5.7 (79) | 5.2 (45) | 6.4 (34) | <0.001 |
Fair | 21.4 (298) | 16.1 (139) | 29.8 (159) | |
Good | 39.3 (548) | 38.9 (335) | 39.9 (213) | |
Very good | 20.7 (289) | 23.3 (201) | 16.5 (88) | |
Excellent | 13.0 (181) | 16.4 (141) | 7.5 (40) | |
Mental health status | ||||
Self-reported mental health status at time of interview (n=1395) | ||||
Poor | 9.5 (132) | 8.1 (70) | 11.6 (62) | <0.001 |
Fair | 21.9 (305) | 20.5 (176) | 24.1 (129) | |
Good | 32.7 (456) | 30.5 (262) | 36.2 (194) | |
Very good | 17.8 (249) | 19.6 (168) | 15.1 (81) | |
Excellent | 18.1 (253) | 21.3 (183) | 13.1 (70) | |
History of abuse | ||||
Proportion who have experienced emotional abuseTable 7 Footnote a (n=1393) | 71.9 (1002) | 65.3 (557) | 82.4 (445) | <0.001 |
Proportion who have experienced physical abuseTable 7 Footnote b (n=1393) | 60.2 (839) | 55.3 (472) | 68.0 (367) | <0.001 |
Proportion who have experienced sexual abuseTable 7 Footnote c (n=1393) | 32.2 (448) | 18.1 (154) | 54.4 (294) | <0.001 |
Proportion who have experienced neglectTable 7 Footnote d (n=1393) | 48.5 (676) | 43.0 (367) | 57.2 (309) | <0.001 |
Proportion who have witnessed violenceTable 7 Footnote e (n=1393) | 76.4 (1064) | 74.7 (637) | 79.1 (427) | 0.060 |
Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on chi square (χ2) statistic.
|
Self-perception of physical and mental health status
Just under three-quarters of participants reported good to excellent physical health (73.0%) and just over two-thirds reported good to excellent mental health (68.6%).
Higher proportions of female participants reported their physical health status as poor (6.4% versus 5.2% for male participants), fair (29.8% versus 16.1% for male participants) or good (39.9% versus 38.9% for male participants). Conversely, higher proportions of male participants reported their physical health status as very good (23.3% versus 16.5% for female participants) or excellent (16.4% versus 7.5% for female participants).
Differences between male and female participants were also observed with self-reported mental health status. Higher proportions of female participants reported their mental health status as poor (11.6% versus 8.1% for male participants), fair (24.1% versus 20.5% for male participants), or good (36.2% versus 30.5% for male participants) and higher proportions of male participants reported their mental health status as very good (19.6% versus 15.1% for female participants) or excellent (21.3% versus 13.1% for female participants).
Self-reported history of abuse (emotional, physical, sexual), experiences of neglect, witnessing violence
Many youth leave home and become street-involved due to conflict, including abuse and violence within their family and home environment.Footnote 13 Experience of abuse directly and indirectly impacts STBBI vulnerability and can affect the sexual risks street-involved youth take. In particular, youth who have been sexually abused in childhood may adopt negative coping mechanisms such as substance use, unprotected sex, and multiple sex partners, all of which increase the risk for STBBIs.Footnote 14
Just under three-quarters of all participants reported experiencing emotional abuse (71.9%), with a significantly higher proportion of female participants reporting experiencing emotional abuse (82.4% versus 65.3% for male participants). Similarly, just under two-thirds of all participants reported physical abuse (60.2%), with a significantly higher proportion of female participants reporting experiencing physical abuse (68.0% versus 55.3% for male participants). Sexual abuse was reported by 32.2% of all participants, with a significantly higher proportion of female participants reporting experiencing sexual abuse (54.4% versus 18.1% for male participants).
Just under half of all participants had experienced neglect (48.5%), with a significantly higher proportion of female participants reporting this (57.2% versus 43.0% for male participants). Just over three-quarters of all participants reported witnessing violence (76.4%); female and male participants did not differ significantly in reporting witnessing violence (79.1% versus 74.7%, respectively).
All participants % (n) |
Male participants % (n) |
Female participants % (n) |
p-value | |
---|---|---|---|---|
Knowledge of health-related services (n=1384) | ||||
Proportion who knew where to go for physical or mental health services | ||||
Yes, know where to go | 87.1 (1206) | 83.9 (712) | 92.3 (494) | <0.001 |
No, don’t know where to go | 12.9 (178) | 16.1 (137) | 7.7 (41) | |
Health-related services ever used (n=1206)Table 8 Footnote a | ||||
Youth drop-in centre | 43.8 (528) | 45.4 (323) | 41.5 (205) | 0.183 |
Walk-in clinic | 32.9 (397) | 33.0 (235) | 32.8 (162) | 0.939 |
Hospital or emergency room | 24.7 (298) | 28.2 (201) | 19.6 (97) | <0.001 |
Family doctor office | 23.4 (282) | 20.9 (149) | 26.9 (133) | 0.016 |
OtherTable 8 Footnote b | 19.7 (237) | 19.5 (139) | 19.8 (98) | 0.892 |
Community organizationTable 8 Footnote c | 19.4 (234) | 20.6 (147) | 17.6 (87) | 0.190 |
Outreach nurseTable 8 Footnote d | 16.8 (203) | 16.9 (120) | 16.8 (83) | 0.981 |
Sexually transmitted infections clinic | 8.0 (96) | 6.6 (47) | 9.9 (49) | 0.036 |
Perceived barriers to accessing health-related servicesTable 8 Footnote e (n=1398) | ||||
Proportion who reported perceived barriers to accessing health-related services | 48.1 (672) | 46.7 (402) | 50.2 (270) | 0.210 |
Types of barriers (of participants who reported any perceived barriers, n=672) | ||||
Lack of a health card | 21.9 (147) | 24.4 (98) | 18.1 (49) | 0.056 |
Long wait times | 16.2 (109) | 16.2 (65) | 16.3 (44) | 0.965 |
OtherTable 8 Footnote f | 13.5 (91) | 13.9 (56) | 13.0 (35) | 0.719 |
Hard to get to health-related services | 12.1 (81) | 10.2 (41) | 14.8 (40) | 0.072 |
Negative experience with health care | 9.7 (65) | 10.4 (42) | 8.5 (23) | 0.407 |
Financial issuesTable 8 Footnote g | 8.5 (57) | 7.5 (30) | 10.0 (27) | 0.247 |
Fear or anxiety around health care | 8.2 (55) | 7.7 (31) | 8.9 (24) | 0.585 |
Limited opportunities to access health- related services | 7.0 (47) | 5.2 (21) | 9.6 (26) | 0.028 |
Transportation issues | 6.7 (45) | 4.7 (19) | 9.6 (26) | 0.013 |
Local social normsTable 8 Footnote h | 6.7 (45) | 7.0 (28) | 6.3 (17) | 0.734 |
Lack of motivation | 5.2 (35) | 5.0 (20) | 5.6 (15) | 0.740 |
Note: Percentages may not sum to 100.0 due to rounding. Where the data in the table contain small cell counts, interpret the results with caution. P-values are based on chi square (χ2) statistic unless otherwise indicated.
|
Health-related service knowledge and use
Over three-quarters of all participants indicated they knew where to go for physical or mental health-related services (87.1%), with a higher proportion of female participants reporting knowing this (92.3% versus 83.9% for male participants). Of the health-related services ever used, participants reported using youth drop-in centres (43.8%), walk-in clinics (32.9%), hospitals or emergency rooms (24.7%), and family doctor offices (23.4%). A significantly higher proportion of male participants reported hospital or emergency room use (28.2% versus 19.6% for female participants), while significantly higher proportions of female participants reported using a family doctor's office (26.9% versus 20.9% for male participants) and an STI clinic (9.9% versus 6.6% for male participants).
Health-related service barriers
Nearly one-half of all participants reported perceived barriers to accessing health-related services (48.1%). The most commonly reported barriers among the 672 participants who reported perceiving them were lack of a health card (21.9%), long wait times (16.2%), hard to get to health-related services (12.1%), negative experiences with health care (9.7%), and financial issues (e.g., lack of extended health insurance coverage; 8.5%). Male and female participants did not differ significantly in how they perceived barriers to accessing health care, except that a higher proportion of female participants reported limited opportunities to accessing health-related services (9.6% versus 5.2% for male participants) and transportation issues (9.6% versus 4.7% for male participants).
Conclusions
Street-involved youth may experience many negative health outcomes caused by poor living conditions on the street, and they may experience barriers that affect their ability to obtain testing, treatment, or care. Footnote 7 Footnote 15 The key findings from the Y-Track Phase 6 analysis demonstrate that the challenges and risk behaviours associated with this sample population are similar to those discussed in the research literature on street-involved youth, and that this sample population is disproportionately impacted by STBBIs compared to Canadian youth overall.
There are some limitations to the Y-Track findings. The survey used non-random sampling, which means that findings may not be representative of all street-involved youth in Canada. In addition, findings are based on self-reported data, which means that certain risk behaviours were over- or underreported. Despite these limitations, findings from Y-Track can be used to evaluate and improve existing health and social support services offered at the local, provincial, and national level to street-involved youth in Canada.
Acknowledgements
The Y-Track surveillance system is possible because of the successful collaboration between the Public Health Agency of Canada and provincial, regional, and local health authorities, researchers, community-based organizations, and participating street-involved youth across Canada. The authors gratefully acknowledge the contribution of the following:
Site-level Contributors
- Vancouver
Dr. Gina Ogilvie (Principal Investigator [PI]), Darlene Taylor, Elaine Jones, Will Steward
BC Centre for Disease Control, Directions Youth Services Centre - Edmonton
Dr. Gerry Predy (PI), Jennifer Gratrix, Josettie Li, Catherine McClintock, Barbara Anderson
Alberta Health Services, Provincial Laboratory for Public Health, Boyle Street Community Services, Hope Mission Youth Unit, Old Strathcona Youth Society, Youth Emergency Shelter Society - Saskatoon
Judith Wright (PI), Johnmark Apondo, Meaghan Friesen, Melody Chlan, Carrie Woods
Saskatoon Health Region, Public Health Services Idylwyld Centre - Winnipeg
John Wylie (PI), Margaret Ormond, Carmen Lopez
Cadham Provincial Laboratory, Ndinawe Shelter, Sage House, Sunshine House - Toronto
Dr. Tony Barazzino (PI), Dr. Miriam Rossi (PI), Dr. Mark Sgro, Magda Melo, Natalie Skira, Ruth Ewert
St. Michael's Hospital, University of Toronto, Hospital for Sick Children, Evergreen Health Centre, Yonge Street Mission - Ottawa
Dana Al-Bargash (PI), Dr. Dara Spatz Friedman (PI), Jacqueline Willmore (PI), Jenna Bennett, Beth O'Halloran
Ottawa Public Health, Operation Come Home, Youth Services Bureau, Public Health Laboratories – Ottawa, Public Health Laboratories – Toronto, The Ottawa Hospital Division of Microbiology - Montréal
Pascale Leclerc (PI), Carole Morissette, Élise Roy, Serge Gallant, Chana Wittenberg, Sébastien Payan, Martine L'Heureux
Direction de la Santé Publique de Montréal, CSSS Jeanne-Mance, Chez Pops, En Marge 12-17, Passages, Ketch Café, Dîner St-Louis, Le Refuge, Auberge communautaire du Sud-Ouest, Maison Tangente - Halifax
Dr. Gaynor Watson-Creed (PI), Kim Barro, Caryll Tawse, Holly D'Angelo-Scott, Amy Burnie, Gina Duggan, Erin Reynolds, Jen LeLievre, Sharon MacIntosh, Susan Mogae, Val Blair, Nancy Chapman, Tammy Callaghan
Capital District Health Authority, Phoenix House, The ARK, Phoenix Shelter, Spring Garden Road Memorial Library, Alderney Gate Library, Halifax North Memorial Library, Direction 180, Barry House, Alderney, Landing, Sackville Library, Captain William Spry Library, YMCA, Metro Turning Point
Other Contributors
- National Laboratory for HIV Reference Services (NLHRS), National Microbiology Laboratory, Public Health Agency of Canada
- Regional Offices, Public Health Agency of Canada
- Centre for Chronic Disease Prevention, Health Promotion and Chronic Disease Prevention, Public Health Agency of Canada
- Communications Directorate, Marketing, Creative Services and E-Comms Division, Public Health Agency of Canada
- Controlled Substances and Tobacco Directorate, Health Canada
- Homelessness Partnering Secretariat, Human Resources and Skills Development Canada
We would also like to acknowledge the efforts and dedication of other colleagues who have helped with the design and implementation of E-SYS since its inception in 1998.
References
- Footnote 1
-
Statistics Canada. Analytical document: Aboriginal peoples in Canada: First Nations People, Métis and Inuit. 2011 National Household Survey [Internet]. Ottawa (ON): Statistics Canada; 2013 [cited 2015 Oct]. Statistics Canada, Catalogue No.: 99-011-X2011001. Available from: http://www12.statcan.gc.ca/nhs-enm/2011/as-sa/99-011-x/99-011-x2011001-eng.pdf
- Footnote 2
-
Public Health Agency of Canada. Summary: estimates of HIV prevalence and incidence in Canada, 2011 [Internet]. Ottawa (ON): PHAC; 2012 [cited 2015 Oct]. Catalogue no. HP37-16/2011E-PDF. Available from: http://publications.gc.ca/collections/collection_2012/aspc-phac/HP37-16-2011-eng.pdf
- Footnote 3
-
Public Health Agency of Canada. Notifiable diseases on-line [Internet]. Ottawa (ON): PHAC; [modified: 2016 Jun 28; cited 2016 Sept 14]. Available at: http://diseases.canada.ca/notifiable/?c=yl
- Footnote 4
-
Public Health Agency of Canada. Report on sexually transmitted infections in Canada: 2010 [Internet]. Ottawa (ON): Public Health Agency of Canada; 2012 [cited 2015 Oct]. Catalogue no. HP37-10/2010E-PDF. Available from: http://publications.gc.ca/collections/collection_2013/aspc-phac/HP37-10-2010-eng.pdf
- Footnote 5
-
Public Health Agency of Canada. Population-specific status report: HIV/AIDS and other sexually transmitted and blood borne infections among youth in Canada [Internet]. Ottawa (ON): Public Health Agency of Canada; 2014 [cited 2015 Oct]. Catalogue no. HP40-43/5-2014E-PDF. Available from: http://www.phac-aspc.gc.ca/aids-sida/publication/ps-pd/youth-jeunes/assets/pdf/youth-jeunes-eng.pdf
- Footnote 6
-
Canadian Centre of Substance Abuse. Substance abuse in Canada: youth in focus. Ottawa (ON): CCSA; 2007. Available from: http://www.ccsa.ca/Resource%20Library/ccsa-011521-2007-e.pdf
- Footnote 7
-
Worthington C, MacLaurin B, Huffey N, Dittmann D, Kitt O, Patten S, Leech J. Calgary youth, health and the street—final report. Calgary (AB): University of Calgary; 2008.
- Footnote 8
-
Health Canada. Canadian Alcohol and Drug Use Monitoring Survey 2010 [Internet]. Ottawa (ON): Health Canada; 2012 [cited 2015 Nov]. Available from: http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2010/summary-sommaire-eng.php
- Footnote 9
-
Statistics Canada. Canadian Tobacco Use Monitoring Survey, 2010: Cycle 2, Person File [public-use microdata file]. Ottawa (ON): Special Surveys Division, Statistics Canada; 2011.
- Footnote 10
-
Adalf EM, Paglia-Boak A. Drug use among Ontario students, 1977-2005: detailed OSDUS findings. Toronto (ON): Centre for Addiction and Mental Health; 2005.
- Footnote 11
-
Miller CL, Strathdee SA, Kerr T, Li K, Wood E. Factors associated with early adolescent initiation into injection drug use: Implications for intervention programs. J Adolesc Health. 2006;38:462-4.
- Footnote 12
-
Kelly K, Caputo T. Health and Street/Homeless Youth. J Health Psychol. 2007;12:726-36.
- Footnote 13
-
McCreary Centre Society. (2002). Between the cracks: Homeless youth in Vancouver. Vancouver: The Society.
- Footnote 14
-
Tarakeshwar N, Fox A, Ferro C, Khawaja S, Kochman A, Sikkema KJ. The connections between childhood sexual abuse and human immunodeficiency virus infection: implications for interventions. J Community Psychol. 2005;33(6):655-72.
- Footnote 15
-
Geber GM. Barriers to health care for street youth. J Adolesc Health, 1997;21(5):287-90.
Appendix I:
Infection | Testing method(s) used | Interpretation of test results |
---|---|---|
HIV | Testing of serum samples was performed using the Bio-Rad GS HIV-1/HIV-2 plus O EIA. Confirmatory testing was subsequently performed using the Innogenetics Inno-LIA HIV I/II Score Assay. | A positive result indicated a current HIV infection. |
Hepatitis B | Hepatitis B testing was performed at local public health labs, as per local testing protocols and algorithms. Testing was done using a series of serological markers that include the following: hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (Anti-HBs) and antibody to hepatitis B core antigen (Anti-HBc). | Different serological combinations indicate current infection (acute or chronic), immunity (natural or vaccine-mediated), and current susceptibility to hepatitis B virus infection. All are of clinical interest. |
Hepatitis C | Testing of serum samples was performed using the Ortho® HCV version 3.0 EIA. Confirmatory testing was subsequently performed using the Innogenetics Inno-LIA HCV Score Assay. | A positive test result indicated a past or current HCV infection, and did not discriminate acute from chronic or resolved infections. |
HSV-1 | Testing of serum samples was performed using the Bionuclear Diagnostics Focus HerpeSelect 1 IgG (EIA screening assay). | A positive test result indicated either a latent or active HSV-1 infection. |
HSV-2 | Testing of serum samples was performed using the Bionuclear Diagnostics Focus HerpeSelect 2 IgG (EIA screening assay). | A positive test result indicated either a latent or active HSV-2 infection. |
Chlamydia | Testing of urine samples was performed using the Roche Amplicor PCR. | A positive test indicated a current chlamydia infection. |
Syphilis | Testing of serum samples was performed using a combination of screening and confirmatory tests including syphilis enzyme immunoassay (EIA), Rapid Plasma Reagin (RPR), T. pallidum particle agglutination assay (TP-PA), and INNO-LIA Syphilis assay. | A positive result was due to the presence of antibodies against syphilis, which indicated either past or present syphilis infection but did not distinguish acute from chronic or resolved infections. |
Gonorrhea | Testing of urine samples was performed using the Roche Amplicor PCR. | A positive test indicated current gonorrhea infection. |
HTLV | Testing of urine samples was performed using the Ortho HTLV I/II Antibody Capture EIA. Confirmatory testing was subsequently performed using Innogenetics INNO-LIA HTLV I/II Score Assay. | A positive result indicated a current HTLV infection. |
Footnotes
- Footnote i
-
The definition of small cell size varies, but it is often defined as a cell count greater than zero but less than three, five, or six, depending on the nature of the data and the source.
- Footnote ii
-
2010 national rates for all youth were used to compare the Y-Track Phase 6 results as 2010 was the midpoint of the 2009 to 2012 Phase 6 data collection period.
- Footnote iii
-
The comparison between 2010 national reported rates for ages 15-24 and the Y-track results should be interpreted with caution. National reported rates only represent a portion of all the cases in the Canadian population and may underestimate actual national rates. Cases may not be reported for the following reasons: not all people will seek medical attention, reporting of diagnosed cases is not complete, diagnostic tests may result in a false negative, interpretation of the characteristics of a disease may vary, and not all provinces or territories are able to report on all diseases in every year.
- Footnote iv
-
CADUMS defines heavy frequent drinker as a person who drinks one or more times per week on average in a year and usually consumes 5 or more drinks on each drinking occasion.
Page details
- Date modified: